What question did this study set out to answer?

To assess the impact of adjuvant systemic therapy on patients with resectable breast cancer.

Adjuvant systemic therapy for resectable breast cancer.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates the effectiveness of adjuvant systemic therapy in resectable breast cancer, suggesting improved outcomes.

To assess the impact of adjuvant systemic therapy on patients with resectable breast cancer.
Conducted a randomized trial evaluating different systemic therapy regimens.
Included patients diagnosed with resectable breast cancer.
Analyzed outcomes related to survival and recurrence rates.
Adjuvant therapy significantly improved overall survival with a hazard ratio (HR) of 0.75, 95% CI 0.60-0.92, p=0.01.
Reduction in recurrence rates observed, particularly in hormone receptor-positive patients.
Overall treatment tolerance was acceptable, with manageable side effects.

Bonadonna et al. (1985) studied this question.

View Full Paper

Ask AI

Bookmark